Weekly Recap | Guardant Health +6.61%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.The Week
Guardant Health (GH) rose 6.61% this week to close at $169.08, while the S&P 500 slipped 0.47%, putting the stock roughly 7.08 percentage points ahead of the benchmark. The week was front-loaded: Monday opened weak and touched a low of $155.00, then price recovered from Tuesday, with a volume-assisted push to around $171.22 on Wednesday. Thursday and Friday consolidated at the highs, finishing the week at $169.08.
Key Events
The main company-specific thread this week was liquid biopsy research. On Tuesday, Guardant Health said it would present 25 liquid biopsy abstracts at ESMO 2026, a development that landed mid-week alongside Wednesday’s volume spike. A Monday report named the company among healthcare stocks riding the AI trade, reflecting sector-level flow. On Friday, an analyst initiated coverage on a bullish note, ranking among the day’s top five initiations. No material company filings were recorded this week after filtering out routine disclosures.
Analyst Ratings
As of 23 October, 27 institutions cover Guardant Health: 21 rate it buy, 4 rate it overweight, 1 rates it underweight, and 1 has no opinion, with no hold or sell ratings. The consensus rating is strong buy, with a consensus target of $201.64, about 19.26% above the latest price. Target prices range from $105.00 to $240.00, a wide spread. The stock ranks first among 53 names in the healthcare services industry.
The Week Ahead
The main company calendar item is the Q3 FY2026 earnings release on Thursday, 5 November, after the market close. Before that, there are no stock-specific events. On the macro side, Tuesday 27 October brings US durable goods orders, consumer confidence, annualised new home sales and house price indices, offering context for rate and growth expectations. With the stock back near $169, the question ahead of earnings is whether the recovery rhythm holds.
In Short
Guardant Health outperformed the broader market this week, with analyst ratings concentrated on the upside and a consensus target about 20% above spot, alongside a top industry ranking. At the same time, P/E and P/B are negative as the company remains unprofitable, and the latest session showed large-lot money as a net seller while small and medium orders were net buyers, a mixed flow picture. The next test is the Q3 earnings print on 5 November.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.